H. Lundbeck A/S & Anor v Sandoz Pty Ltd; CNS Pharma Pty Ltd v Sandoz Pty Ltd

The Full Federal Court of Australia heard appeals in two related proceedings: *H. Lundbeck A/S & Anor v Sandoz Pty Ltd* and *CNS Pharma Pty Ltd v Sandoz Pty Ltd*. The dispute concerned allegations of patent infringement and invalidity relating to pharmaceutical products. H. Lundbeck A/S and CNS Pharma Pty Ltd (the appellants) alleged that Sandoz Pty Ltd (the respondent) had infringed their patents by manufacturing and supplying generic versions of certain antidepressant medications. Sandoz denied infringement and counterclaimed that the asserted patents were invalid.

The primary legal issues before the Full Federal Court were whether the respondent had infringed the appellants' patents, and if so, whether those patents were valid. Specifically, the court had to consider the scope of the patent claims, the doctrine of equivalents, and the grounds for invalidity, including lack of novelty, inventive step, and insufficient disclosure. The appeals concerned the interpretation and application of the *Patents Act 1990* (Cth) and relevant case law concerning pharmaceutical patents.

The Full Federal Court's reasoning focused on a detailed analysis of the patent specifications and the respondent's products. The court applied established principles of patent law, including the approach to claim construction, the assessment of inventive step, and the requirements for sufficiency. The court found that the respondent's products did not fall within the literal scope of the patent claims. Furthermore, the court considered whether the doctrine of equivalents applied, examining whether the respondent's products achieved substantially the same result in substantially the same way as the patented invention, with the same essential elements. The court ultimately determined that the patents were invalid on grounds of insufficient disclosure and lack of inventive step, and that there was no infringement.

The Full Federal Court allowed the appeals in part, setting aside the primary judge's findings on infringement but upholding the primary judge's findings on invalidity. The court declared the relevant patents invalid and ordered that the appellants pay the respondent's costs of the appeals.